GGI
LCTX icon

Godsey & Gibb Inc’s Lineage Cell Therapeutics LCTX Stock Holding History

Godsey & Gibb Inc’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-500
Closed -$1K – 119
2021
Q3 		$1K Hold
500
– – ﹤0.01% 91
2021
Q2 		$1K Buy
+500
New +$1.29K ﹤0.01% 91

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Godsey & Gibb Inc's LCTX Position: Q4 2021 in Review

Godsey & Gibb Inc sold out of Lineage Cell Therapeutics (LCTX) in Q4 2021, closing a stake of 500 shares — an estimated $1K sold.

Godsey & Gibb Inc first reported a position in LCTX in Q2 2021 and held it in 2 quarters. The position peaked at $1K in Q3 2021. 124 funds tracked by Wall St. Rank hold LCTX as of Q4 2021.

  • Godsey & Gibb Inc reported no remaining Lineage Cell Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Godsey & Gibb Inc sold 500 Lineage Cell Therapeutics shares in Q4 2021, an estimated $1K.
  • Godsey & Gibb Inc first reported a position in Lineage Cell Therapeutics in Q2 2021 and held it in 2 quarters.
  • Godsey & Gibb Inc's Lineage Cell Therapeutics position peaked at $1K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2021.

Based on Godsey & Gibb Inc's 13F filing for Q4 2021, filed 15 Feb 2022.